Goldman Sachs has racked up its third pharmaceuticals deal in weeks after working on a $2.5bn (€2bn) US transaction which follows two European deals worth $19bn last month.

Gilead Sciences, a US drug manufacturer for life-threatening infectious diseases, has agreed to acquire rival Myogen, which makes medicines for cardiovascular diseases.